Trial
NCT05653427
A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Carcinoma, Hepatocellular
Intervention
Amivantamab
Why stopped
N\~15 subjects data analysis did not meet statistical consideration of ORR and study primary/secondary objectives were not met. Enrollment was terminated for futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-01-13